• 1. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 2. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 3. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 4. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 5. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551

• Solvents and Organic Chemicals Organic Compounds Organohalogen compounds Aryl halides Aryl chlorides

Introduction to 4-Chloro-1-(1-Methyl-1H-Pyrazol-4-yl)methyl-1H-Pyrazol-3-amine (CAS No. 1004452-03-2)

4-Chloro-1-(1-methyl-1H-pyrazol-4-yl)methyl-1H-pyrazol-3-amine (CAS No. 1004452-03-2) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, also known as CPMPA, is characterized by its unique structural features, which include a chlorinated pyrazole ring and a methylated pyrazole moiety. These structural elements contribute to its potential biological activities and therapeutic applications.

The chemical structure of CPMPA consists of a central pyrazole ring with a chloro substituent at the 4-position and a methylated pyrazole moiety attached via a methylene bridge. The presence of these functional groups imparts specific physicochemical properties to the molecule, such as solubility, stability, and reactivity. These properties are crucial for its use in various biological assays and drug development processes.

Recent studies have highlighted the potential of CPMPA in several therapeutic areas. One notable application is in the treatment of neurological disorders, particularly those involving serotonin and dopamine signaling pathways. Research has shown that CPMPA can modulate these neurotransmitter systems, potentially offering new avenues for the treatment of conditions such as depression, anxiety, and Parkinson's disease.

In addition to its neurological applications, CPMPA has been investigated for its anti-inflammatory properties. In vitro studies have demonstrated that this compound can inhibit the production of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These findings suggest that CPMPA may have therapeutic potential in inflammatory diseases like rheumatoid arthritis and multiple sclerosis.

The pharmacokinetic profile of CPMPA has also been studied extensively. It has been found to exhibit good oral bioavailability and a favorable distribution pattern, allowing it to reach target tissues effectively. Furthermore, the compound shows low toxicity in preclinical studies, making it a promising candidate for further development.

Clinical trials are currently underway to evaluate the safety and efficacy of CPMPA in human subjects. Early results from phase I trials have indicated that the compound is well-tolerated at various dose levels, with no serious adverse effects reported. These findings are encouraging and pave the way for more advanced clinical studies.

The synthesis of CPMPA involves several steps, including the formation of the pyrazole ring and subsequent functionalization with the chloro and methyl groups. Various synthetic routes have been developed to optimize yield and purity, ensuring that the compound meets stringent quality standards for pharmaceutical use.

In conclusion, 4-Chloro-1-(1-methyl-1H-pyrazol-4-yl)methyl-1H-pyrazol-3-amine (CAS No. 1004452-03-2), or CPMPA, is a promising compound with diverse biological activities and therapeutic potential. Ongoing research continues to uncover new applications and mechanisms of action, further solidifying its importance in the field of medicinal chemistry. As clinical trials progress, it is hoped that this compound will contribute significantly to the development of new treatments for various diseases.

• 261629-02-1(3-amino-1-propyl-1H-Pyrazole-4-carbonitrile)
• 3524-31-0(1-(Pyridin-4-ylmethyl)-1H-pyrazol-5-amine)
• 145864-65-9(1H-Pyrazole-4-carboxamide,5-amino-1-ethyl-)
• 122800-01-5(3-Amino-1-benzyl-1H-pyrazole-4-carbonitrile)
• 21254-23-9(5-Amino-1-isopropyl-1H-pyrazole-4-carbonitrile)
• 114936-29-7(3-amino-1-methyl-1H-Pyrazole-4-carboxylic acid hydrazide)
• 5346-53-2(5-Amino-1-(2-hydroxyethyl)-1H-pyrazole-4-carbonitrile)
• 3528-58-3(1-Ethyl-1H-pyrazol-5-amine)
• 3524-49-0(1,4-Dimethyl-1H-pyrazol-5-amine)
• 158001-28-6(5-amino-1-tert-butyl-pyrazole-4-carbonitrile)